Friday, August 15, 2014

New Engagement - Revolutionsry Big Data Clinical Decision Support Analysis Engine and Database

Big Data Analysis Engine Optimizes Disease Treatment & Speeds Drug Discovery      

  • Initial "Freemium" version has 15,336 registered users with the highest concentration coming from (in order) The US National Institute of Health, Harvard’s Dana Farber Cancer Research Center, Stanford Medical School, Johns Hopkins, The Mayo Clinic, M.D. Anderson, and Mt. Sinai

  • Super computational AI systems biology machine has read the entire US National Library of Medicine Medline Archive, extracted all key clinical outcome data from over 200 years of research and integrated it into real time treatment optimization and new cure discovery solutions.

  • Database tracks: 11,600 diseases and rates247,600 drugs and biological agents1,224 therapeutic techniques and 1,416 pharma companies for achieved successful clinical outcomes
  • Commercialized Products and Services: Company solutions are productized as 1. evidence-based publications of best treatment options for patients,  2. Outcome-centric on line real time Clinical Decision Support Systems for physicians, and 3. Contract Services for new drug discovery real time drug repurposing for pharma manufacturers.
The Company's Systems Biology Machine was designed to meet the NIH "Bench to Bedside Program" goal for rapid translation of pure research into an Evidence-Based Medicine System usable in real time at the point of clinical care, and the FDA "Critical Path Initiative" goal for rapid discovery of new cures using built in CA-DDD: Computer Aided Drug Discovery and Development models.

Operationally, Company products are  web browser-accessible applications easily integrated  into all software as service solutions from leading health information/EMR Cloud providers seeking to improve patient outcomes through Personalized Medicine, evidence-targeted therapies, and side by side cost  to efficacy comparative data.  The company’s clinical outcome database is the largest in the world based solely on proven clinical efficacy and is directly integrated with Network Graph Theory algorithms for new cure discovery. Its use preempts futile path investments in the hundreds of millions of R&D dollars.  The ability of the Company's Machine to autonomously discover new cures for human disease—in 3-4 minutes of computation--has been formally demonstrated to the NSF, NIH, and FDA.  Early adopter sales have been made for each product line segment.

Our Client has engaged MidMarket Capital to locate a Strategic Buyer / Investor that could capitalize on their world class technology solution, leverage their intellectual property and scale into a very large and receptive market space.

We are exclusively representing this Company to your firm as part of an offering to a select group of qualified investors.

Dropbox Link for Profile and NDA


Dave Kauppi is a Merger and Acquisition Advisor and Managing Director of MidMarket Capital, providing business broker and investment banking services to owners in the sale of information technology companies. To view our lists of buyers and sellers click to visit our Web Site MidMarket Capital

No comments:

Post a Comment